Literature DB >> 18509348

The prognostic value of haemodynamic parameters in the recovery phase of an exercise test. The Finnish Cardiovascular Study.

T Nieminen1, J Leino, J Maanoja, K Nikus, J Viik, T Lehtimäki, T Kööbi, R Lehtinen, K Niemelä, V Turjanmaa, M Kähönen.   

Abstract

We tested the hypothesis that the change from the peak to recovery values of systolic arterial pressure (SAP recovery) and rate-pressure product (RPP recovery) can be used to predict all-cause and cardiovascular mortality, as well as sudden cardiac death (SCD) in patients referred to a clinical exercise stress test. As a part of the Finnish Cardiovascular Study (FINCAVAS), consecutive patients (n=2029; mean age+/-SD=57+/-13 years; 1290 men and 739 women) with a clinically indicated exercise test using a bicycle ergometer were included in the present study. Capacities of attenuated SAP recovery, RPP recovery and heart rate recovery (HRR) to stratify the risk of death were estimated. During a follow-up (mean+/-s.d.) of 47+/-13 months, 122 patients died; 58 of the deaths were cardiovascular and 33 were SCD. In Cox regression analysis after adjustment for the peak level of the variable under assessment, age, sex, use of beta-blockers, previous myocardial infarction and other common coronary risk factors, the hazard ratio of the continuous variable RPP recovery (in units 1000 mm Hg x b.p.m.) was 0.85 (95% CI: 0.73-0.98) for SCD, 0.87 (0.78-0.97) for cardiovascular mortality, and 0.87 (0.81 to 0.94) for all-cause mortality. SAP recovery was not a predictor of mortality. The relative risks of having HRR below 18 b.p.m., a widely used cutoff point, were as follows: for SCD 1.28 (0.59-2.81, ns), for cardiovascular mortality 2.39 (1.34-4.26) and for all-cause mortality 2.40 (1.61-3.58). In conclusion, as a readily available parameter, RPP recovery is a promising candidate for a prognostic marker.

Entities:  

Mesh:

Year:  2008        PMID: 18509348     DOI: 10.1038/jhh.2008.38

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  6 in total

1.  Combination of low blood pressure response, low exercise capacity and slow heart rate recovery during an exercise test significantly increases mortality risk.

Authors:  Kalle Sipilä; Antti Tikkakoski; Sanni Alanko; Atte Haarala; Jussi Hernesniemi; Leo-Pekka Lyytikäinen; Jari Viik; Terho Lehtimäki; Tuomo Nieminen; Kjell Nikus; Mika Kähönen
Journal:  Ann Med       Date:  2019-11-07       Impact factor: 4.709

2.  Circadian variation in the circulatory responses to exercise: relevance to the morning peaks in strokes and cardiac events.

Authors:  Greg Atkinson; Helen Jones; Philip N Ainslie
Journal:  Eur J Appl Physiol       Date:  2009-10-14       Impact factor: 3.078

3.  Long-term intra-individual reproducibility of heart rate dynamics during exercise and recovery in the UK Biobank cohort.

Authors:  Michele Orini; Andrew Tinker; Patricia B Munroe; Pier D Lambiase
Journal:  PLoS One       Date:  2017-09-05       Impact factor: 3.240

4.  Association of Blood Pressure Responses to Submaximal Exercise in Midlife With the Incidence of Cardiovascular Outcomes and All-Cause Mortality: The Framingham Heart Study.

Authors:  Joowon Lee; Ramachandran S Vasan; Vanessa Xanthakis
Journal:  J Am Heart Assoc       Date:  2020-05-20       Impact factor: 5.501

5.  Cardiovascular Autonomic Function Changes and Predictors During a 2-Year Physical Activity Program in Rheumatoid Arthritis: A PARA 2010 Substudy.

Authors:  David Hupin; Philip Sarajlic; Ashwin Venkateshvaran; Cecilia Fridén; Birgitta Nordgren; Christina H Opava; Ingrid E Lundberg; Magnus Bäck
Journal:  Front Med (Lausanne)       Date:  2021-12-15

6.  South Asians have elevated postexercise blood pressure and myocardial oxygen consumption compared to Europeans despite equivalent resting pressure.

Authors:  Nish Chaturvedi; Rajaram Bathula; Angela C Shore; Ronney Panerai; John Potter; Jaspal Kooner; John Chambers; Alun D Hughes
Journal:  J Am Heart Assoc       Date:  2012-10-25       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.